Health Care·Pharmaceuticals·$789.7B
Eli Lilly and Co (LLY) is a major player in the pharmaceuticals sector, focusing on innovative treatments for various health conditions, including diabetes and cancer. With a market cap of $820 billion, the company is significant in the healthcare landscape, especially as it navigates ongoing developments in drug approvals and market competition.
Earnings Per Share (EPS)
EPS is a crucial indicator of profitability and helps investors gauge the company's financial health.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
3Q
EPS Beat Rate
75%
Avg EPS Surprise
+8.40%
Avg Stock Reaction
+0.10%
In Q4 2025, Eli Lilly reported an EPS of $7.54, exceeding expectations by nearly 8%. This positive surprise continues a trend of strong earnings performance.
Management Promises & Guidance
Analysts are generally optimistic about Eli Lilly's upcoming earnings, expecting strong EPS and revenue growth driven by its product portfolio.
Bull Case
If Eli Lilly beats EPS estimates, it could signal robust demand for its therapies and potentially lead to upward revisions in future guidance.
Bear Case
Conversely, if the company misses EPS expectations, it may raise concerns about its growth trajectory and competitive pressures in the pharmaceutical market.
Earnings Per Share (EPS)
$6.84EPS is a crucial indicator of profitability and helps investors gauge the company's financial health.
Revenue
$17.8BRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will the EPS exceed the consensus estimate of $6.84?
A beat on EPS could reinforce investor confidence in the company's growth and profitability.
Q2
What are the revenue figures compared to the consensus of $17.8B?
Revenue performance will indicate the effectiveness of Eli Lilly's sales strategies and market demand for its products.
Why consensus could be wrong
The Street may underestimate the impact of recent product launches on revenue growth, especially in the diabetes segment.
Supporting Evidence
Recent trends show increased demand for diabetes medications, which could drive higher sales than anticipated.
Options pricing suggests a move of 5%, but historical data indicates the stock has often reacted more strongly to positive surprises.
Key Risk
If revenue significantly exceeds $18B, it could challenge the current market expectations and lead to upward revisions.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will reflect the company's ability to maintain its growth momentum amidst market challenges.
Bull Confirmed If
An EPS of $7.00 or higher would confirm strong demand and operational success.
Bear Confirmed If
An EPS below $6.50 would raise concerns about market competitiveness and growth sustainability.
Implied Move
±5%
Historical Avg
±8.1%
The options market is pricing in a potential move of about 5% in either direction following the earnings report.
Options are pricing ±5.1% while LLY has averaged ±8.1% over the last 8 prints — setup is pricing cheap.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Eli Lilly beats expectations, history suggests a potential average one-day move of +4.1%, confirming strong operational performance.
In-Line / Cautious
An inline result may lead to muted market reactions, with management commentary being crucial for future guidance.
Miss
If the company misses expectations, history suggests a potential average one-day move of -0.74%, indicating investor disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026